Talasila Eswara Gopala Krishna Murthy

Type 2 diabetes mellitus requires combination therapy to achieve effective glycemic control. Bilayer tablet formulations combining immediate and sustained drug release offer improved therapeutic outcomes. Glimepiride and Metformin hydrochloride are commonly prescribed together due to their complementary mechanisms of action. The aim of the current research was to formulate bilayer tablets of Glimepiride and Metformin hydrochloride to enhance therapeutic utility in the management of type 2 diabetes mellitus. Bilayer tablets were developed with Glimepiride in the immediate-release layer using the superdisintegrant croscarmellose sodium, and Metformin hydrochloride in the sustained-release layer using microcrystalline cellulose and HPMC K100M as key excipients. The formulations were optimized by evaluating immediate-release characteristics of Glimepiride and sustained-release profiles of Metformin hydrochloride. The optimized formulation (F6) demonstrated 99.92% immediate release of Glimepiride within 45 minutes, while Metformin hydrochloride showed a sustained release of 99.87% over a period of 12 hours. The study indicates the successful development of bilayer tablets of Glimepiride and Metformin hydrochloride, which can be effectively used for the management of type 2 diabetes mellitus.

The recent emergence of COVID-19 influenced the layman’s knowledge of drugs. Although several drugs have been discovered serendipitously, research has moved to the next-generation era of drug disco... Lay abstract Despite existing therapies for various ailments, emerging diseases or disorders need more selective treatments. Traditionally ‘pharmacy’ is thought of as a medical store, but time has ... Tweetable abstract How pharmacy’s core research domains provide strong support for both basic and translational drug discovery research.

The objective of the present research work was to develop a multi-particulate modified release system of Fenofibric acid using Wurster (Bottom spray fluid bed coating) process. Impact of various formulation variables was assessed by using statistical interpretation such as ANOVA. A 33 (three factor, three level) face centered central composite design was employed to study the effect of independent variables (concentration of ER Polymer, plasticizer and pore former), on dependent variables (drug release at 2.5th h & 6th h). Optimization of the formulation variables was done by fitting experimental data to the software program (Design Expert). The design space for formulation variables was developed. Fabricated pellets were characterized for various physico-chemical parameters. In vitro release data of the optimized formulation was fitted into various kinetic equations. The optimized formulation showed a desired drug release at both 2.5th h and 6th h as 17.5 ± 2.28% & 87.1 ± 0.75% respectively. The drug release from the capsules followed first order kinetics and controlled by non fickian transport. The information acquired in this study recommends that the multi-particulates of Fenofibric acid can be effectively intended to give a delayed release of Fenofibric acid and thus enhanced bioavailability.

The present paper illustrates about development and validation of a new, simple, precise and accurate RP-HPLC method with enhanced sensitivity for the simultaneous determination of Doxylamine Succinate (DAS) and Pyridoxine Hydrochloride (PDH) in bulk and its dosage forms. The drug showed good...

Aims: To develop Ivabradine HCl floating pulsatile multiparticulate (beads/ pellets) dosage forms containing calcium alginate beads/ pellets coated with pH-dependent polymer Eudragit S 100, by ionic gelation, pan coating, fluidized bed coating techniques and optimization of technique by comparing evaluation parameters with statistical data.